Carbamazepine (All indications)

Congenital heart defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S9653
R34359		 Bànhidy (Carbamazepine), 2011 Cardiovascular congenital abnormalities throughout pregnancy case control unexposed, sick Adjustment: No Matched 0.80 [0.16;3.88] C 4/14   5/15 9 14
ref
Total 1 studies 0.80 [0.16;3.88] 9 14
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bànhidy (Carbamazepine), 2011Bànhidy, 2011 1 0.80[0.16; 3.88]9140%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: lowROB mesure: moderateROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Carbamazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0 case control studiescase control studies 0.80[0.16; 3.88]914 -NABànhidy (Carbamazepine), 2011 1 Type of controls unexposed, sickunexposed, sick 0.80[0.16; 3.88]914 -NABànhidy (Carbamazepine), 2011 1 Tags Adjustment   - No  - No 0.80[0.16; 3.88]914 -NABànhidy (Carbamazepine), 2011 1 MatchedMatched 0.80[0.16; 3.88]914 -NABànhidy (Carbamazepine), 2011 1 All studiesAll studies 0.80[0.16; 3.88]914 -NABànhidy (Carbamazepine), 2011 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.60; 1.67]18,2084,60839%NACohen (Carbamazepine) (Mixed indications) (Controls unexposed, NOS), 2023 Ban (Carbamazepine) (Mixed indications) (Controls unexposed NOS), 2015 Källén (Carbamazepine) (Controls unexposed, NOS) (Indications NOS), 2013 Mawer (Carbamazepine) (Controls unexposed, disease free), 2010 D'Souza (Carbamazepine) (Controls unexposed, disease free), 1991 Van der Pol (Carbamazepine) (Controls unexposed, disease free), 1991 6 unexposed, sick controlsunexposed, sick controls 0.66[0.35; 1.25]411,8630%NAThomas (Carbamazepine) (Controls unexposed, sick), 2021 Vajda (Carbamazepine) (Controls unexposed, sick), 2013 Bànhidy (Carbamazepine), 2011 Mawer (Carbamazepine) (Controls unexposed, sick), 2010 Artama (Carbamazepine), 2005 Canger (Carbamazepine), 1999 D'Souza (Carbamazepine) (Controls unexposed, sick), 1991 Van der Pol (Carbamazepine) (Controls unexposed, sick), 1991 8 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.36[0.97; 1.90]1458,1030%NAThomas (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2021 Tomson (Carbamazepine), 2018 Ban (Carbamazepine) (Mixed indications) (Controls exposed to Lamotrigine, sick), 2015 Campbell (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2014 Veiby (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Källén (Carbamazepine) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 Vajda (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2013 Hernández-Díaz (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2012 Mawer (Carbamazepine) (Controls exposed to Lamotrigine, sick), 2010 90.510.01.0